In the heart of Southeast Asia, Indonesia is part of a revolutionary shift: a genomics-based healthcare revolution that promises to create new opportunities and foster economic growth.
While investments in genomics-related ventures were relatively novel in 2018, we have invested in leading genomics startups, such as NalaGenetics and Nusantics, as a clear demonstration of our unwavering belief. But our support does not stop there; we actively back initiatives that accelerate genomics research and innovation while collaborating with stakeholders.
East Ventures and NalaGenetics are committed to supporting the genomic analysis of the Indonesian population at Biomedical and Genome Science Initiative (BGSi). East Ventures extends sequencing support in the form of consumables valued at IDR 1,022,395,458.
We believe that investing in genomics is an investment for the future. East Ventures remains steadfast in its commitment to forge a productive and healthy Southeast Asia for today, tomorrow, and more generations to come.
Find us at:
Instagram: @eastventures
Twitter: @eastventures
Facebook: eastventuresofficial
LinkedIn: East Ventures